Zidovudine removal during plasma exchange

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Immunology

Background:

• Zidovudine (azidothymidine, AZT) is a key antiretroviral medication used in HIV treatment.
• Plasma exchange is a therapeutic apheresis technique used in various medical conditions.
• The potential impact of plasma exchange on drug pharmacokinetics, specifically AZT, requires investigation.

Purpose of the Study:

• To investigate the pharmacokinetics of zidovudine (AZT) in a human immunodeficiency virus (HIV) seropositive patient undergoing plasma exchange.
• To determine the extent to which plasma exchange influences AZT elimination and clearance.

Main Methods:

• Oral administration of zidovudine (300 mg every 8 hours) to an HIV-positive patient.
• Therapeutic plasma exchange (60 ml/kg) performed concurrently with AZT administration.
• Quantification of plasma AZT concentrations using high-performance liquid chromatography (HPLC).

Main Results:

• Plasma exchange clearances for AZT ranged from 1% to 3.8% of total body clearance.
• Only approximately 1% of the administered AZT dose was removed from the separated plasma.
• The contribution of plasma exchange to the overall elimination of AZT was found to be negligible.

Conclusions:

• Plasma exchange has a minimal effect on the elimination of zidovudine (AZT).
• Based on pharmacokinetic data, no specific dose adjustments for AZT are indicated in patients receiving multiple plasma exchange treatments.
• Further studies may be warranted to confirm these findings in a larger patient cohort.